filmov
tv
Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
Показать описание
JAMA Network
5121641307001
women's health
breast cancer
cancer survivorship
Endocrinology
Рекомендации по теме
0:03:01
Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
0:24:33
Session 9: Adjuvant endocrine therapy for premenopausal women: Risk stratification, type & durat...
0:22:14
Adjuvant endocrine therapy in postmenopausal women: Risk stratification, type & duration
0:01:56
Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
0:02:30
monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancer
0:06:09
Adjuvant endocrine therapy for breast cancer: optimal durations and regimens
0:01:50
Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast Cancer
0:48:22
Adjuvant Endocrine Therapy for high-risk breast cancer
1:41:26
Education Session: Trends in Adjuvant Endocrine Therapy
0:01:56
Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast Cancer
0:02:47
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
0:04:18
Adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-...
0:01:26
Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer
0:10:02
Breast Cancer: Extended Adjuvant Endocrine Therapy
0:01:04
Dr. Mamounas on Adjuvant Endocrine Therapy for Breast Cancer
0:02:10
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
0:30:20
Optimizing adjuvant endocrine therapy for early Breast Cancer
0:46:31
Adjuvant Therapy | 2023 Best of Breast Conference
0:04:54
Adjuvant Hormonal Therapy for Estrogen Receptor Positive Early Stage Breast Cancer - Mayo Clinic
0:05:00
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
0:00:29
Adjuvant treatment for high risk HR+ breast cancer | ESMO 2023 Breast Cancer Highlights
0:47:22
Dr. Aju Mathew, Assistant Professor of Medicine talking on Breast Cancer at our Foster City Lab
0:05:32
ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer
0:00:45
Is there a potential benefit of intermediate duration of adjuvant endocrine therapy?